Cover storyCDMO Trends 2026: What’s Driving Mergers And Acquisitions
CDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.
Cover storyCDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.

FDA classifies Capricor's Deramiocel BLA amendment as major, extending the PDUFA date to November 22, 2026 after submission of 24-month HOPE-3 data.

Insmed's MHLW approval of brensocatib for NCFB completes a US-EU-Japan regulatory arc, marking the first approved treatment in the indication across all three major markets.

ANI Pharmaceuticals adds M&A veteran Henry Gosebruch to its board as the company accelerates its rare disease consolidation strategy.

EU approves teclistamab plus daratumumab for second-line RRMM, based on Phase 3 MajesTEC-3 survival data.
Latest edition

Sep 28
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
